Pay in 4 interest-free payments of $11.25 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b
It inhibits Ack1 and germinal center kinase (GCK)
115088-06-7
1 μM canertinib inhibits ErbB1-3 receptor phosphorylation with a concomitant decrease of Akt-
9 mg/mL (Need ultrasonic or warming)
BI-9564 - BRD9 Bromodomain Inhibitor. CAS# 1883429-22-8 size:2 mg solid Prevalence of hepatitis C virusBI 9564, CAS No. 1883429 22 8, is a potent and selective inhibitor of BRD9 and BRD7 bromodomains (Kds = 14. 1 and 239 nM; IC50s = 75 nM and 3. 4 M, respectively). BI 9564 is useful in further exploring BRD9 bromodomain biology in both in vitro and in vivo settings. Selective inhibitors of bromodomain containing protein 9 (BRD9) may have therapeutic potential in the treatment of human malignancies and inflammatory diseases. Product information CAS
US$ 387.79
US$ 116.96
US$ 83.71